Sec. 6703. Prohibition on intelligence community contracting with Chinese military companies engaged in biotechnology research, development, or manufacturing
708 words·~3 min read·
/bill/119/s/1071/eah/section-6703A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
In this section: The term 1260H list means the list of Chinese military companies operating in the United States most recently submitted under section 1260H(b)(1) of the William M.
(Mac)Thornberry National Defense Authorization Act for Fiscal Year 2021 ( 10 U.S.C. 113 note). The term affiliate means an entity that directly or indirectly controls, is controlled by, or is under common control with another entity. The term biotechnology means the use of biological processes, organisms, or systems for manufacturing, research, or medical purposes, including genetic engineering, synthetic biology, and bioinformatics. Subject to subsections
(d)and (e), a head of an element of the intelligence community may not enter into, renew, or extend any contract for a product or service with— any entity listed on the 1260H list that is engaged in biotechnology research, development, or manufacturing activities; any entity that is a known or assessed affiliate of any entity described in paragraph (1); any entity that has a known or assessed joint venture, partnership, or contractual relationship with any entity described in paragraph (1), if the Director of National Intelligence determines that the relationship presents a risk to the national security of the United States; or any other entity that is engaged in biotechnology research, development, or manufacturing activities, if the Director of National Intelligence determines that the activities present a risk to the national security of the United States. The Director of National Intelligence shall, in consultation with the heads of the elements of the intelligence community— establish guidelines for the implementation of this section; maintain both a publicly available and classified list of entities covered by the prohibition in subsection (b); require that each head of an element of the intelligence community ensure that any contractor engaged by the element certify that neither it nor any of its subcontractors are engaged in a contract for a product or service with an entity covered by the prohibition in subsection (b); and otherwise ensure compliance with subsection (b). The Director of National Intelligence may establish a waiver process for the heads of the elements of the intelligence community under which the head of the relevant element may waive the prohibition under subsection
(b)for a procurement on a case-by-case basis. A waiver may be made under the process only if the head of the relevant element— complies with any conditions the Director may establish for the process; and determines, in writing, that— the procurement is essential for national security and no reasonable alternative source exists; and appropriate measures are in place to mitigate risks associated with the procurement. For each waiver for a procurement issued under subsection (b), the Director and the relevant head of the element of the intelligence community shall, not later than 30 days after issuing the waiver, submit to the congressional intelligence committees, the Committee on Appropriations of the Senate, and the Committee on Appropriations of the House of Representatives a notice of the waiver, which shall include a justification for the waiver and a description of the risk mitigation measures implemented for the procurement. The prohibition in subsection
(b)shall not apply to— the acquisition or provision of health care services overseas for— employees of the United States, including members of the uniformed services (as defined in section 101(a) of title 10, United States Code), whose official duty stations are located overseas or who are on permissive temporary duty travel overseas; or employees of contractors or subcontractors of the United States— who are performing under a contract that directly supports the missions or activities of individuals described in subparagraph (A); and whose primary duty stations are located overseas or who are on permissive temporary duty travel overseas; or the acquisition, use, or distribution of human multiomic data, lawfully compiled, that is commercially or publicly available. This section shall take effect on the date that is 60 days after the date of the enactment of this Act and apply to any contract entered into, renewed, or extended on or after such effective date. The provisions of this section shall terminate on the date that is 10 years after the date of the enactment of this Act. This section shall only be construed to apply to activities of an element of the intelligence community.
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 6703
Prohibition on intelligence community contracting with Chinese military companies engaged in biotechnology research, development, or manufacturing
Cites 1Cited by 0 across 0 sources